Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 ...
Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer Demonstration of Cyclin E1 protein overexpression as an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results